Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Capital Expenditures (2020 - 2025)

Insight Molecular Diagnostics' Capital Expenditures history spans 6 years, with the latest figure at $1.0 million for Q3 2025.

  • For Q3 2025, Capital Expenditures rose 1106.9% year-over-year to $1.0 million; the TTM value through Sep 2025 reached $1.9 million, up 239.22%, while the annual FY2024 figure was $516000.0, 83.63% up from the prior year.
  • Capital Expenditures for Q3 2025 was $1.0 million at Insight Molecular Diagnostics, up from $349000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $1.6 million in Q1 2022 and bottomed at -$564000.0 in Q3 2023.
  • The 5-year median for Capital Expenditures is $394000.0 (2021), against an average of $500529.4.
  • The largest annual shift saw Capital Expenditures surged 1813.64% in 2021 before it tumbled 165.66% in 2023.
  • A 5-year view of Capital Expenditures shows it stood at $401000.0 in 2021, then skyrocketed by 100.0% to $802000.0 in 2022, then crashed by 67.08% to $264000.0 in 2023, then decreased by 18.94% to $214000.0 in 2024, then surged by 390.65% to $1.0 million in 2025.
  • Per Business Quant, the three most recent readings for IMDX's Capital Expenditures are $1.0 million (Q3 2025), $349000.0 (Q2 2025), and $307000.0 (Q1 2025).